Study on Amivantamab and Capmatinib Combination Therapy for Advanced Non-Small Cell Lung Cancer

Inclusion Criteria

• Diagnosed with advanced non-small cell lung cancer (NSCLC) that cannot be surgically removed.
• May have brain metastases that have been treated and are stable without symptoms for more than 2 weeks, and are either not on steroids or on a low dose (10 mg or less of prednisone or equivalent) for at least 2 weeks before starting the study.
• May have had another type of cancer in the past, as long as it does not interfere with the study treatment.
• Have a good overall health status, with an ECOG performance score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Women of childbearing potential must have a negative pregnancy test before starting the study and agree to regular pregnancy tests during the study.

Exclusion Criteria

• Have a history of lung diseases like interstitial lung disease (ILD) or pneumonitis, or currently have these conditions.
• Have digestive issues that could affect how the body absorbs capmatinib, or cannot swallow tablets.
• Have brain metastases that are causing symptoms or require increasing doses of steroids (more than 10 mg of prednisone or equivalent) within 2 weeks before starting the study.
• Have uncontrolled pain from tumors that could be treated with radiation therapy, such as bone metastases or tumors pressing on nerves, and have not been treated at least 7 days before starting the study.